nitrates has been researched along with Hypertension, Renal in 26 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conclude that hypoxia-induced HTN is associated with depressed NO production and can be mitigated by L-arginine supplementation." | 3.70 | Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension. ( Bemanian, S; Kivlighn, SD; Ni, Z; Vaziri, ND, 1998) |
| " Mechanistically, oxidative stress and compromised function of the nitric oxide synthase (NOS) system leading to endothelial dysfunction and reduction in nitric oxide (NO) bioavailability have been widely implicated and associated with development and progression of disease." | 2.61 | Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease. ( Carlstrom, M; Montenegro, MF, 2019) |
| " A reduction in NO bioavailability in early life may contribute to the initiation of glomerular and tubular dysfunction that promotes development and progression of hypertension in offspring with a congenital nephron deficit, including those with a SFK." | 1.43 | Renal Nitric Oxide Deficiency and Chronic Kidney Disease in Young Sheep Born with a Solitary Functioning Kidney. ( Booth, LC; Denton, KM; Easton, LK; Head, GA; Moritz, KM; Schlaich, MP; Singh, RR, 2016) |
| "Reduced bioavailability of endogenous nitric oxide (NO) is a central pathophysiological event in hypertension and other cardiovascular diseases." | 1.37 | Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. ( Carlström, M; Hezel, M; Larsson, E; Lundberg, JO; Persson, AE; Scheffer, PG; Teerlink, T; Weitzberg, E, 2011) |
| "Captopril treatment reversed the increments in pressure back to normal values by the fourth week." | 1.33 | Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat. ( Al-Shabanah, O; Khattab, MM; Mostafa, A, 2005) |
| " The role of renal immune cell infiltration, oxidative stress, and nitric oxide bioavailability in the pathogenesis was investigated." | 1.33 | Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. ( Jung, FF; Manning, J; Stewart, T; Vehaskari, VM, 2005) |
| "Children attending the above centre for treatment of hypertension." | 1.30 | Nitric oxide activity in childhood hypertension. ( Dillon, MJ; Goonasekera, CD; Rees, DD; Shah, V, 1997) |
| "Captopril treatment protected rats receiving L-NAME and none of the captopril-treated rats died." | 1.30 | Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. ( Eriksson, A; Fyhrquist, F; Holthöfer, H; Miettinen, A; Tikkanen, I; Tikkanen, T; Törnroth, T; Uhlenius, N, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 15 (57.69) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Paula, TD | 1 |
| Silva, BR | 1 |
| Grando, MD | 1 |
| Pernomian, L | 1 |
| do Prado, AF | 1 |
| Bendhack, LM | 1 |
| Carlstrom, M | 2 |
| Montenegro, MF | 1 |
| Singh, RR | 1 |
| Easton, LK | 1 |
| Booth, LC | 1 |
| Schlaich, MP | 1 |
| Head, GA | 1 |
| Moritz, KM | 1 |
| Denton, KM | 1 |
| Rajapakse, NW | 1 |
| De Miguel, C | 1 |
| Das, S | 1 |
| Mattson, DL | 1 |
| Sasser, JM | 1 |
| Moningka, NC | 1 |
| Cunningham, MW | 1 |
| Croker, B | 1 |
| Baylis, C | 3 |
| Persson, AE | 1 |
| Larsson, E | 1 |
| Hezel, M | 1 |
| Scheffer, PG | 1 |
| Teerlink, T | 1 |
| Weitzberg, E | 1 |
| Lundberg, JO | 1 |
| Zhou, XJ | 1 |
| Vaziri, ND | 2 |
| Zhang, J | 1 |
| Wang, HW | 1 |
| Wang, XQ | 1 |
| Al-Nimri, MA | 1 |
| Komers, R | 1 |
| Oyama, TT | 1 |
| Subramanya, AR | 1 |
| Lindsley, JN | 1 |
| Anderson, S | 1 |
| Kawada, N | 1 |
| Dennehy, K | 1 |
| Solis, G | 1 |
| Modlinger, P | 1 |
| Hamel, R | 1 |
| Kawada, JT | 1 |
| Aslam, S | 1 |
| Moriyama, T | 1 |
| Imai, E | 1 |
| Welch, WJ | 1 |
| Wilcox, CS | 1 |
| Wesseling, S | 1 |
| Ishola, DA | 1 |
| Joles, JA | 1 |
| Bluyssen, HA | 1 |
| Koomans, HA | 1 |
| Braam, B | 1 |
| Xia, CF | 1 |
| Bledsoe, G | 1 |
| Chao, L | 2 |
| Chao, J | 2 |
| Khattab, MM | 1 |
| Mostafa, A | 1 |
| Al-Shabanah, O | 1 |
| Stewart, T | 1 |
| Jung, FF | 1 |
| Manning, J | 1 |
| Vehaskari, VM | 1 |
| Bivol, LM | 1 |
| Berge, RK | 1 |
| Iversen, BM | 1 |
| Schneider, MP | 1 |
| Ge, Y | 1 |
| Pollock, DM | 1 |
| Pollock, JS | 1 |
| Kohan, DE | 1 |
| del Castillo, D | 1 |
| Raij, L | 1 |
| Shultz, PJ | 1 |
| Tolins, JP | 1 |
| Faria, MS | 1 |
| Muscará, MN | 1 |
| Moreno Júnior, H | 1 |
| Teixeira, SA | 1 |
| Dias, HB | 1 |
| De Oliveira, B | 1 |
| Graeff, FG | 1 |
| De Nucci, G | 1 |
| Goonasekera, CD | 1 |
| Shah, V | 1 |
| Rees, DD | 1 |
| Dillon, MJ | 1 |
| Ni, Z | 1 |
| Bemanian, S | 1 |
| Kivlighn, SD | 1 |
| Uhlenius, N | 1 |
| Tikkanen, T | 1 |
| Miettinen, A | 1 |
| Holthöfer, H | 1 |
| Törnroth, T | 1 |
| Eriksson, A | 1 |
| Fyhrquist, F | 1 |
| Tikkanen, I | 1 |
| Schmidt, RJ | 2 |
| Yokota, S | 1 |
| Tracy, TS | 1 |
| Sorkin, MI | 1 |
| Kim, SW | 1 |
| Lee, J | 1 |
| Kang, DG | 1 |
| Jung, K | 1 |
| Kim, NH | 1 |
| Suh, SP | 1 |
| Choi, KC | 1 |
| Kang, YJ | 1 |
| Venkatakrishnan, U | 1 |
| Chen, C | 1 |
| Lokhandwala, MF | 1 |
| Wolf, WC | 1 |
| Yoshida, H | 1 |
| Agata, J | 1 |
| Nafz, B | 1 |
| Seeliger, E | 1 |
| Persson, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234] | Phase 4 | 32 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -0.66 |
| Metoprolol | -2.35 |
The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 2.16 |
| Metoprolol | 10.43 |
"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -1.07 |
| Metoprolol | -3.19 |
Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | -8.14 |
| Metoprolol | 8.70 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol < 50 Years Old | 51.55 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: Baseline and Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol <50 Year Old | 51.55 |
| Metoprolol >/= 50 Year Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol >/=50 Years Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: 12 Months
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Nebivolol | 50.07 |
| Metoprolol | 38.13 |
Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 11.47 |
| Metoprolol | -17.27 |
Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -2.65 |
| Metoprolol | -3.88 |
1 review available for nitrates and Hypertension, Renal
| Article | Year |
|---|---|
Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease.
Topics: Biological Availability; Humans; Hypertension, Renal; Nephritis; Nitrates; Nitric Oxide; Nitric Oxid | 2019 |
25 other studies available for nitrates and Hypertension, Renal
| Article | Year |
|---|---|
Relaxation induced by the nitric oxide donor and cyclooxygenase inhibitor NCX2121 in renal hypertensive rat aortas.
Topics: Animals; Aorta, Thoracic; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; | 2017 |
Renal Nitric Oxide Deficiency and Chronic Kidney Disease in Young Sheep Born with a Solitary Functioning Kidney.
Topics: Animals; Disease Models, Animal; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertens | 2016 |
Exogenous L-arginine ameliorates angiotensin II-induced hypertension and renal damage in rats.
Topics: Albuminuria; Angiotensin II; Animals; Arginine; Blood Pressure; Consciousness; Creatinine; Drug Inte | 2008 |
Asymmetric dimethylarginine in angiotensin II-induced hypertension.
Topics: Amidohydrolases; Angiotensin II; Animals; Arginine; Blood Pressure; Fibrosis; Hypertension, Renal; K | 2010 |
Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension.
Topics: Animals; Arginine; Blood Pressure; Cardiomegaly; Disease Models, Animal; Hypertension, Renal; Kidney | 2011 |
Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Hypertension, | 2002 |
Endothelial-derived vasoactive mediators in polycystic kidney disease.
Topics: Animals; Blood Pressure; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Hypertension, Renal | 2003 |
TP receptors regulate renal hemodynamics during angiotensin II slow pressor response.
Topics: 6-Ketoprostaglandin F1 alpha; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Rece | 2004 |
Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT2 receptor.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Blood Pressure; Female; Fre | 2005 |
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.
Topics: Animals; Cell Cycle Proteins; Cell Division; Cyclic GMP; Cyclin-Dependent Kinase Inhibitor p27; Deso | 2005 |
Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartate Aminotransferases; Blood Pressure; Body | 2005 |
Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension.
Topics: Animals; Antioxidants; Cell Movement; Cyclic N-Oxides; Female; Hypertension, Renal; Immunosuppressiv | 2005 |
Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension.
Topics: Animals; Body Weight; Chemokine CCL2; Dinoprost; Disease Models, Animal; Eating; Free Radical Scaven | 2008 |
Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide.
Topics: Animals; Blood Pressure; Diuresis; Endothelin-1; Enzyme Inhibitors; Heart Rate; Hypertension, Renal; | 2008 |
The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system.
Topics: Animals; Blood Pressure; Disease Models, Animal; Erythropoietin; Hematocrit; Hydrogen-Ion Concentrat | 1995 |
Acute inhibition of nitric oxide synthesis induces anxiolysis in the plus maze test.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Arginine; Blood Pressure; Brain; Centra | 1997 |
Nitric oxide activity in childhood hypertension.
Topics: Biomarkers; Child; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hypertension | 1997 |
Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension.
Topics: Acetamides; Animals; Arginine; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonis | 1998 |
Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Pre | 1999 |
Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis.
Topics: Adult; Aged; Arginine; Citrulline; Creatinine; Cyclic GMP; Female; Humans; Hypertension, Renal; Kidn | 1999 |
Erythropoietin does not affect nitric oxide system in rats with chronic renal failure.
Topics: Acetylcholine; Anemia; Animals; Aorta, Thoracic; Body Weight; Erythropoietin; Hypertension, Renal; I | 2000 |
The role of intrarenal nitric oxide in the natriuretic response to dopamine-receptor activation.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Enzyme Inhibitors; | 2000 |
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Topics: Adenoviridae; Animals; Blood Pressure; Blood Urea Nitrogen; Cardiomegaly; Cyclic GMP; Fibrosis; Gene | 2000 |
Total nitric oxide production is low in patients with chronic renal disease.
Topics: Adult; Aged; Arginine; Blood Pressure; Creatinine; Female; Humans; Hypertension, Renal; Kidney Failu | 2000 |
Nitric oxide and the role of blood pressure variability to the kidney.
Topics: Animals; Blood Pressure; Dogs; Hypertension, Renal; Kidney; Nitrates; Nitric Oxide; Potassium; Renal | 2001 |